title: [Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment].
abstract: OBJECTIVE
  To diagnose diffuse large B-cell lymphosarcoma (DLBCLS) with primary involvement of the mediastinal lymph nodes (LN) and to evaluate the efficiency of aggressive polychemotherapy (PCT).
  
  
  METHODS
  The study included 15 patients (6 men and 9 women aged 18 to 70 years; median 38 years) followed up at the Hematology Research Center, Russian Academy of Medical Sciences, in 2004 to 2009. Three and 12 patients had Stages II and IE DLBCLS, respectively. B symptoms were found in 14 (93.4%) patients. Increased lactate dehydrogenase (LDH) concentrations were detectable in 14 (93.4%) patients; tumors of 10 cm or more (bulky disease) were seen in 11 (73.3%). Enlarged cervical, supraclavicular, and axillary lymph nodes were found in 9 (60%) patients; lung involvement via extension in 9 (60%), and invasion into the pericardium in 5 (33.3%) and soft tissues of the anterior thoracic wall in (13.3%). There were no signs of involvement of extranodal organs at the moment of diagnosis. All the 15 patients received PCT according to the modified NHL-BFM-90 program: 4 to 6 courses depending on the response to the therapy; 10 (66.6%) and 5 (33.3%) patients had 4 and 6 courses, respectively; for consolidating purpose, 11 (78.5%) patients were prescribed radiotherapy applied to the mediastinum in a cumulative dose of 36 Gy due to the fact that they had a residual mass.
  
  
  RESULTS
  Thirteen (86.6%) patients achieved a complete remission (CR). Primary PCT resistance was confirmed in one case. Another patient was stated to have near-complete remission. No recurrences were notified during the follow-up. The mean CR duration was 24.5 (range 2-49) months.
  
  
  CONCLUSIONS
  DLBCLS with primary LN involvement is an individual nosological entity to be differentiated from primary mediastinal large B-cell lymphosarcoma. In most cases, DLBCLS shows signs of a poor prognosis, which makes it necessary to perform aggressive PCT.
authors.forename: Ia K
authors.initials: IaK
authors.lastname: Mangasarova
authors.forename: A U
authors.initials: AU
authors.lastname: Magomedova
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: V I
authors.initials: VI
authors.lastname: Vorob'ev
authors.forename: D S
authors.initials: DS
authors.lastname: Mar'in
authors.forename: A V
authors.initials: AV
authors.lastname: Gubkin
authors.forename: N I
authors.initials: NI
authors.lastname: Skidan
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: I A
authors.initials: IA
authors.lastname: Vorob'ev
authors.forename: R S
authors.initials: RS
authors.lastname: Samoĭlova
authors.forename: A I
authors.initials: AI
authors.lastname: Vorob'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D008297:Male; D008479:Mediastinal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D008482:Mediastinum / Q000000981:diagnostic imaging; D008875:Middle Aged; D009367:Neoplasm Staging; D011877:Radionuclide Imaging; D014463:Ultrasonography; D055815:Young Adult
chemical_list: D015703:Antigens, CD